The introduction of three new antiretroviral medicines for treating people with HIV could save $3 billion for programmes in low- and middle-income countries by the end of 2025. This finding was presented in February at the world's premier HIV science meeting: the Conference on Retroviruses and Opportunistic Infections, better known as CROI.
Read the full article here.
